Proteomics for Identification of Hyperoxia-induced Changes in Protein Expression

September 16, 2015 updated by: Dr. med. Stefan Braunecker, University Hospital of Cologne

Aim of the present study is to investigate the influence of hyperoxia on the protein expression using the differential analysis of protein expression in tissues (proteomics). In the study, blood and urine samples will be collected from participants who undergo a short term hyperoxia using 100% oxgen for 3 hours.

Here, gel electrophoresis, protein separation and mass spectroscopy allow to identify affected proteins. Based on these results, different induction factors of proteins will be determined and then assessed using a bioinformatic network analysis regarding the cellular influence.

Study Overview

Status

Unknown

Conditions

Detailed Description

Oxygen is necessary to sustain human life and is used for energy production by oxidation in the mitochondria. Application of oxygen not only increases saturation in the patient's blood, but also has various secondary effects. It is therefore used to treat diseases that impairs body's ability to take up and use oxygen. But even healthy people can suffer from hypoxia when they ascend to high altitude. Here, altitude sickness can lead to potentially fatal complications such as high altitude cerebral edema or high altitude pulmonary edema. Since hypoxia can have disastrous consequences, hyperoxia is often tolerated in many pre- and in-hospital situations.

Whereas the effects of hypoxia are well studied, especially publications in the last decade have led to a new perspective on oxygen application. Besides pathophysiological changes as the peripheral vasoconstriction or reduction of contractility, especially changes on cellular level seem to be of great importance. Here, oxidative stress and change of protein synthesis in various organ are focus of current studies.

The differential analysis of protein expression in tissues (proteomics) is an important approach for better understanding of the negative effects of hyperoxia. Especially for patients with long-term high oxygen demand the knowledge of cellular changes during hyperoxia can result in new therapeutic approaches and a reduction in the rate of complications.

In the present molecular biology study urine and blood samples of healthy volunteers will be collected at specified times after short-term exposure to oxygen. These samples will be analyzed after the study using the differential analysis of protein expression. The aim of this study is to investigate the effects of oxygen on the cell functions by analyzing and subsequent bioinformatic processing of differentially regulated proteins in the blood and urine.

After checking the inclusion and exclusion criteria biometric data of the test persons are collected.

Before short-term hyperoxia a sample collection of blood and urine will be performed. Here the participants are taken 5 ml of venous blood from the cephalic vein under sterile conditions. To obtain the urine sample spontaneous urine of participants is used. The samples are immediately centrifuged and flash frozen at -80°C. In order to exclude impairment of the lung prior to the short-term hyperoxia a pulmonary function test is carried out by using a hand spirometer.

To induce hyperoxia subjects inhale 100% oxygen for 3 hours through a face mask.

After carrying out the short term hyperoxia the follow up phase takes place. In this phase blood and urine samples from the subjects will be obtained directly after the hyperoxia (T0), on day 1 (T1), day 3 (T3), day 7 (T7), day 14 (T14), day 21 (T21) and day 28 (T28) after oxygen exposure. All samples will be centrifuged immediately after collection and flash frozen at -80 ° C. To exclude hyperoxia-induced lung impairments, a spirometry is performed during the follow up.

After the samples of all subjects were collected the analysis of the samples will be carried out using Proteomics.

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • American Society of Anesthesiologists (ASA) 1
  • >18 years
  • < 50 years

Exclusion Criteria:

  • American Society of Anesthesiologists (ASA) > 1
  • pregnant
  • <18 years
  • > 50 years
  • frequent or recent drug intake

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Hyperoxia
Participants receive 100% oxygen
Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Comparison of proteomics changes before and after short-term hyperoxia
Time Frame: 4 weeks
4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Spirometry Results: Forced vital capacity (FVC) [L]
Time Frame: 2 days
Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.
2 days
Spirometry Results: Forced expiratory volume at one second (FEV1) [L]
Time Frame: 2 days
Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.
2 days
Spirometry Results: Forced expiratory flow (FEF25-75) [L/s]
Time Frame: 2 days
Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.
2 days
Spirometry Results: Peak expiratory flow (PEF) [L/s]
Time Frame: 2 days
Spirometry will be used as a measure of safety to rule out adverse events of oxygen to the lung.
2 days
Vital parameter: Respiratory rate (RR) [1/min]
Time Frame: 3 hours
Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.
3 hours
Vital parameter: Heart rate (HR) [1/min]
Time Frame: 3 hours
Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.
3 hours
Vital parameter: Blood pressure (BP) [mmHg]
Time Frame: 3 hours
Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.
3 hours
Vital parameter: Oxygen saturation (SpO2) [%]
Time Frame: 3 hours
Vital parameters will be used as a measure of safety to rule out adverse events of oxygen to the vascular system.
3 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Stefan Braunecker, M.D., Universityhospital of Cologne

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2015

Primary Completion (ANTICIPATED)

October 1, 2016

Study Completion (ANTICIPATED)

December 1, 2016

Study Registration Dates

First Submitted

July 9, 2015

First Submitted That Met QC Criteria

September 16, 2015

First Posted (ESTIMATE)

September 17, 2015

Study Record Updates

Last Update Posted (ESTIMATE)

September 17, 2015

Last Update Submitted That Met QC Criteria

September 16, 2015

Last Verified

September 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 15-109

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hyperoxia

Clinical Trials on Oxygen (FiO2 1,0)

Subscribe